Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
Product liability claims alleging, among other things, an association between diabetes drugs like Byetta and pancreatic cancer (http://www.byettalawsuit.com/byetta-pancreatic-cancer/) continue to move forward in state and federal courts around the country, Bernstein Liebhard LLP reports. According to court documents, a joint status conference was convened last week in the federal and state incretin mimetics litigations currently underway in California. According to an Order issued on January 17, 2014 in the U.S. District Court, Southern District of California, the two proceedings are being coordinated. (In Re: Incretins Products Liability, Sales and Marketing Litigation, MDL 2452)
The Order also noted that there are now 35 Byetta lawsuits pending in the federal multidistrict litigation that allege use of the drug caused plaintiffs to suffer thyroid cancer. According to the document, a Byetta lawsuit involving pancreatitis allegations is scheduled to go to trial in California Superior Court on February 18, 2014. (In re: Byetta Cases, JCCP No. 4574)
http://www.digitaljournal.com/pr/1700673
The Order also noted that there are now 35 Byetta lawsuits pending in the federal multidistrict litigation that allege use of the drug caused plaintiffs to suffer thyroid cancer. According to the document, a Byetta lawsuit involving pancreatitis allegations is scheduled to go to trial in California Superior Court on February 18, 2014. (In re: Byetta Cases, JCCP No. 4574)
http://www.digitaljournal.com/pr/1700673